VP01 is a small molecule compound for oral administration, which is in clinical development for the treatment of interstitial lung diseases (ILDs). The experimental programme will assess the potential of VP01 for treatment of idiopathic pulmonary fibrosis (IPF) and in systemic sclerosis (SSc) where fibrosis/vasculopathy is a significant aspect of the disease process. VP01 has been recognized as an orphan drug in IPF by the regulatory authorities in Europe and the USA. Vicore has received approval from the UK authority MHRA for a phase II study with VP01 in IPF. This study will collect information on the safety and efficacy outcomes of VP01 in these patients. The study design has been modified in order to maximize the statistical power to detect a treatment effect, as well as reduce the number of patients needed, hence potentially shortening the time to read-out. In Q2 2020 the company announced that this study will also recruit patients in India. The study will include 60 patients and the observed treatment effect of VP01 for six months will be compared with the well-documented linear decline of lung function in untreated patients.